Innovator Astra settled patent litigation with Teva pending in the U.S. District Court for the District of New Jersey
After first settling with first paara IV filer Ranabxy in April, 2008, innovator M/S AstraZeneca has entered into a licensing agreement with generic player Teva and as per terms of the settlement Teva would be able to launch the generic version in May 27, 2014 (after the expiry of two key Orange Book listed patents US5877192 and US6875872), onwards.
Teva has admitted the validity of following Orange Book patents:
US5,690,960
US5,714,504
US5,877,192
US5,900,424
US5,948,789
US6,428,810
US6,369,085
US6,875,872
US7,411,070
The other generic players like Sandoz, Dr. Reddy's and Lupin are in patent litigation with innovator, the litigation is pending in New Jersey District Court.
No comments:
Post a Comment